phrykt

Aquestive Therapeutics, Inc. (AQST): who owns it and who trades it

As of Nov 16, 2026, AQST insiders reported 17 open-market sales worth $2.4M and 2 purchases worth $99.3K in the last 12 months, with 32% of the sale value made under pre-set 10b5-1 plans. The largest seller was Daniel Barber (CEO), with $1.3M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Aquestive Therapeutics

From the latest filings

Overall: more buying than selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns AQST

185 funds and institutions reported AQST shares worth $301M at the end of Q2 2026, about 59% of the company. The largest holder is Bratton Capital Management, L.P. with 8.0%.

Funds and institutions (13F) 59%Everyone else 41%

10 largest owners, by share of the company

Bratton Capital Management, L.P.8.0%
BlackRock, Inc.6.6%
Rtw Investments, LP6.1%
Vanguard Capital Management LLC3.8%
Federated Hermes, Inc.2.6%
State Street Corp2.4%
Geode Capital Management, LLC2.1%
Samsara Biocapital, LLC2.0%
Bank of America Corp1.4%
Sio Capital Management, LLC1.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Bratton Capital Management, L.P.9.81M8.04%$40.8MNo change
BlackRock, Inc.8.07M6.61%$33.6M+7%
Rtw Investments, LP7.43M6.09%$30.9MNo change
Vanguard Capital Management LLC4.58M3.76%$19.1M+3%
Federated Hermes, Inc.3.11M2.55%$12.9M+6%
State Street Corp2.93M2.40%$12.2M+15%
Geode Capital Management, LLC2.62M2.15%$10.9M+9%
Samsara Biocapital, LLC2.50M2.05%$10.4MNo change
Bank of America Corp1.67M1.37%$6.9M-31%
Sio Capital Management, LLC1.49M1.22%$6.2M-23%
Propel Bio Management, LLC1.44M1.18%$6M+103%
Wasatch Advisors LP1.39M1.14%$5.8M+58%
Two Sigma Investments, LP1.28M1.05%$5.3M+12%
Nuveen, LLC1.22M1.00%$5.1M+379%
Janney Montgomery Scott LLC1.11M0.91%$4.6M+2%
Wells Fargo & Company1.09M0.89%$4.5M+5%
Commonwealth Equity Services, LLC1.05M0.86%$4.4M-3%
Barclays PLC996,6650.82%$4.1M+25%
Blue Owl Capital Holdings LP942,9320.77%$3.9M-30%
Northern Trust Corp831,1510.68%$3.5M+13%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, AQST insiders reported $99.3K of open-market purchases and $2.4M of sales. 32% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$99.3K
2 trades, 1 people
Sales, 12 months
$2.4M
17 trades, 9 people
Sales under a 10b5-1 plan
32%
Share of sale value
Latest trade
Nov 12, 2026
Filed Nov 16, 2026

Purchases and sales by month

$1.7M$1.7MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 12, 2026Matthew W. DavisChief Development OfficeSale plan7,197$3.55$25.5KForm 4
Nov 10, 2026Richard J DalyDirectorPurchase1,200$3.53$4.2KForm 4
Nov 10, 2026Richard J DalyDirectorPurchase26,825$3.54$95.1KForm 4
Oct 15, 2026Daniel BarberCEOSale plan25,000$4.22$106KForm 4
Sep 15, 2026Daniel BarberCEOSale plan25,000$4.82$120KForm 4
Sep 9, 2026Sherry KorczynskiChief Commercial OfficerSale plan8,750$5.22$45.7KForm 4
Aug 17, 2026Daniel BarberCEOSale plan25,000$4.29$107KForm 4
Jul 16, 2026Daniel BarberCEOSale plan20,369$4.00$81.5KForm 4
Jul 15, 2026Daniel BarberCEOSale plan4,631$4.03$18.7KForm 4
Jun 23, 2026Julie KropDirectorSale plan25,000$5.02$125KForm 4
Jun 15, 2026Daniel BarberCEOSale plan25,000$4.16$104KForm 4
May 15, 2026Daniel BarberCEOSale plan8,257$4.29$35.4KForm 4
Mar 10, 2026Peter E. BoydChief People OfficerSale29,814$4.17$124KForm 4
Mar 10, 2026Daniel BarberCEOSale180,677$4.17$753KForm 4
Mar 10, 2026Lori J BraenderChief Legal OfficerSale40,102$4.17$167KForm 4
Mar 10, 2026Melina CioffiVice presidentSale25,311$4.17$106KForm 4
Mar 10, 2026A Ernest Toth JrCFOSale58,254$4.17$243KForm 4
Mar 10, 2026Sherry KorczynskiChief Commercial OfficerSale15,741$4.17$65.6KForm 4
Mar 10, 2026Cassie JungChief Operating OfficerSale45,791$4.17$191KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Daniel BarberPresident and CEO–$1.3MOct 15, 2026
A Ernest Toth JrChief Financial Officer–$243KMar 10, 2026
Cassie JungChief Operating Officer–$191KMar 10, 2026
Lori J BraenderChief Legal Officer–$167KMar 10, 2026
Julie KropDirector–$125KJun 23, 2026
Peter E. BoydChief People Officer–$124KMar 10, 2026
Sherry KorczynskiChief Commercial Officer–$111KSep 9, 2026
Melina CioffiSVP, Regulatory Affairs–$106KMar 10, 2026
Richard J DalyDirector$99.3K–Nov 10, 2026
Matthew W. DavisChief Development Officer–$25.5KNov 12, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AQST short interest

Very high short interest. 23.3% of AQST shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went up 95%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 29.32M AQST shares were sold short, 23.3% of the shares outstanding, up 6.2% from the report before. At the average daily volume of 2.21M shares, buying them all back would take about 13.2 trading days (days to cover).

Shares short, % of all shares

23.3%May 15Oct 3025.0%

Days to cover

13.2May 15Oct 3015.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202629.32M23.33%+6%2.21M13.2
Oct 15, 202627.60M21.99%-4%1.99M13.9
Sep 30, 202628.75M22.90%+6%2.20M13.1
Sep 15, 202627.16M21.64%+7%2.30M11.8
Aug 31, 202625.48M20.30%+22%3.56M7.2
Aug 14, 202620.95M16.69%+16%4.04M5.2
Jul 31, 202618.05M14.79%+8%2.02M8.9
Jul 15, 202616.67M13.66%+4%1.53M10.9
Jun 30, 202616.00M13.11%+8%3.03M5.3
Jun 15, 202614.80M12.12%-3%1.55M9.6
May 29, 202615.24M12.49%+1%1.41M10.8
May 15, 202615.03M12.32%-3%2.02M7.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Aquestive Therapeutics company events

Aquestive Therapeutics filed 18 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026AnnouncementShared information with investors. Filing
  2. Nov 3, 2026ResultsReleased financial results. Filing
  3. Oct 19, 2026RulesChanged its bylaws or articles. Filing
  4. Oct 15, 2026AnnouncementShared information with investors. Filing
  5. Oct 14, 2026AgreementAquestive Therapeutics, Inc. entered into a license agreement with Eton Pharmaceuticals, Inc. pursuant to which the Company granted Eton exclusive U.S. rights to commercialize LIBERVANT® (diazepam) buccal film for the acute treatment of seizure clusters in patients with epilepsy, subject to… Filing
  6. Sep 29, 2026LeadershipAquestive Therapeutics, Inc. announced that the Board of Directors of the Company has elected Richard J. Daly as a director of the Company, effective October 14, 2026. Filing
  7. Sep 25, 2026AnnouncementShared information with investors. Filing
  8. Sep 17, 2026AnnouncementThe Company issued a press release announcing it has resubmitted its New Drug Application to the U.S. Food and Drug Administration for Anaphylm™ (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis. Filing
  9. Aug 11, 2026ResultsReleased financial results. Filing
  10. Aug 10, 2026AnnouncementAquestive Therapeutics, Inc. issued a press release announcing the results from its human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film, conducted in support of the Company’s planned resubmission of its New Drug Application to the U.S. Food and… Filing
  11. Jun 10, 2026VoteReported shareholder vote results. Filing
  12. May 13, 2026AgreementAquestive Therapeutics, Inc. entered into a five-year term loan facility of up to $150.0 million, consisting of a term loan in an of $55.0 million that was funded on the Effective Date, a term loan in an of $20.0 million available subject to certain terms and conditions, a term loan in an of $25.0… Filing
  13. Mar 30, 2026AnnouncementShared information with investors. Filing
  14. Mar 20, 2026LeadershipAquestive Therapeutics, Inc. and Lori J. Braender, Chief Legal Officer, Chief Compliance Officer and Corporate Secretary of the Company, agreed that Ms. Braender will step down from her Chief Legal Officer and Chief Compliance Officer roles and will no longer serve as an executive officer of the… Filing
  15. Mar 4, 2026AgreementAquestive Therapeutics, Inc. entered into Amendment No. 1 to the Purchase and Sale Agreement, dated August 13, 2025, with funds managed by RTW Investments, LP. Filing
  16. Feb 26, 2026AnnouncementShared information with investors. Filing
  17. Feb 2, 2026AnnouncementShared information with investors. Filing
  18. Jan 9, 2026AnnouncementAquestive Therapeutics, Inc. issued a press release announcing the receipt of a notice from the U.S. Food and Drug Administration (FDA) that, as part of its ongoing review, the FDA had identified deficiencies in the New Drug Application (NDA) submitted by the Company for its product candidate… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Aquestive Therapeutics financials

Famous investors that hold AQST

3 of the 50 well-known investors we track reported holding AQST in their latest 13F filing. The largest position is Ken Griffin's, worth $3.7M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026809,853$3.7M0.0%+79%
Israel Englander · Millennium ManagementQ3 2026687,058$3.2M0.0%New
Jim Simons · Renaissance TechnologiesQ3 2026558,472$2.6M0.0%+34%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named AQST in the last 120 days.

FiledHolderFormStake
Oct 7, 2026Bass Edward P13G7.5%
Oct 7, 2026Bass Edward P13G7.5%
Oct 7, 2026BRATTON DOUGLAS K13G/A0.6%
Oct 7, 2026BRATTON DOUGLAS K13G/A0.6%

Questions about Aquestive Therapeutics, Inc. (AQST) stock

Who owns the most AQST stock?

The largest reported owner of Aquestive Therapeutics, Inc. (AQST) is Bratton Capital Management, L.P., with 8.0% of the company. In total, 185 funds and institutions reported holding AQST at the end of Q2 2026, together about 59% of the shares. See the largest owners.

Are AQST insiders buying or selling?

In the last 12 months, AQST insiders reported 2 open-market purchases worth $99.3K and 17 sales worth $2.4M. The latest trade was on Nov 12, 2026. See every trade.

What is the short interest in AQST?

As of Oct 30, 2026, 29.32M AQST shares were sold short, 23.3% of the shares outstanding, up 6.2% from the report before. At the average daily volume of 2.21M shares, buying them all back would take about 13.2 trading days (days to cover). See the history.

Which famous investors hold AQST?

3 of the 50 well-known investors we track reported AQST in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $3.7M. See all holders.

Executive pay

Aquestive Therapeutics's chief executive was paid a total of $3.5M for the year ended Dec 31, 2025, down 16% from $4.2M the year before. In the last 12 months, Aquestive Therapeutics's executives and directors bought $99.3K of stock on the open market and sold $2.4M.

Chief executive, total pay$3.5MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$11MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.